Ming Ji, Ph.D.

Scientist III
BASF Corporation

Poster(s):

• (M0930-01-03) Overcoming Direct Compression Issues in Omeprazole Formulations Using Co-Processed Excipient vs. Wet Granulation
  Monday, October 21, 2024

  9:30 AM – 10:30 AM MT

• (T0930-10-59) In Vitro and In Vivo Correlations of Danazol-SEDDS Formulations Using MacroFLUX^TM and miniFLUX™
  Tuesday, October 22, 2024

  9:30 AM – 10:30 AM MT

• (T1030-09-49) Analyzing the Characteristics of HME Extruded Material in Pharmaceutical 3D Printing: Formulation, Printability, and Dissolution Study
  Tuesday, October 22, 2024

  10:30 AM – 11:30 AM MT

• (M1030-09-51) Development of 3D Printed Oral Disintegrating Tablets of Oxcarbazepine Using Co-Processed Excipient
  Monday, October 21, 2024

  10:30 AM – 11:30 AM MT

• (W1030-10-55) Optimizing Tablet Formulation through Integrated Use of Digital Formulation Tools and Compaction Simulation
  Wednesday, October 23, 2024

  10:30 AM – 11:30 AM MT

• (W1230-10-56) Efficient Manufacturing of Omeprazole Modified-Release Minitablets Using “All-in-One” Co-Processed Excipient and Talc-Free Aqueous Coating System
  Wednesday, October 23, 2024

  12:30 PM – 1:30 PM MT

• (T1330-04-19) Non-Gelatin Film Coatings for Formulating Easy-to-Swallow Tablets
  Tuesday, October 22, 2024

  1:30 PM – 2:30 PM MT

• (T1430-02-11) Alcohol Dose Dumping in Modified Release Formulations: Critical Considerations for Regulatory Guidance(s)
  Tuesday, October 22, 2024

  2:30 PM – 3:30 PM MT

• (M1530-10-56) Enhancing the Solubilization and Permeation of Fenofibrate: A Comparative Study of Free Form, PEG and SEDDS Formulations
  Monday, October 21, 2024

  3:30 PM – 4:30 PM MT